JCR Pharmaceuticals (4552) Earnings: Revenue up 13.2% YoY, Operating Loss of 2,103 Million Yen

JCR Pharmaceuticals Co., Ltd. (4552) announced its latest financial results, reporting net sales of 9,700 million yen, representing a 13.2% increase compared to the same period of the previous year. However, on the earnings front, the company recorded an operating loss of 2,103 million yen, an ordinary loss of 2,084 million yen, and a net loss attributable to owners of the parent of 1,907 million yen. Earnings per share (EPS) stood at -15.64 yen.

From a financial structure and valuation perspective, the equity-to-asset ratio is maintained at 40.6%, showing a moderate level of financial stability. Retained earnings stand at 28.1 billion yen, alongside interest-bearing debt of 53.94 billion yen. Regarding profitability indicators, return on equity (ROE) was -4.50%, return on assets (ROA) was -1.80%, and EBITDA was -2.1 billion yen. While top-line growth is evident, improving profitability remains a key focus for future performance.